Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company’s lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. The company was formerly known as Chinook Therapeutics U.S., Inc. and changed its name to Chinook Therapeutics, Inc. in October 2020. Chinook Therapeutics, Inc. was incorporated in 2015 and is headquartered in Seattle, Washington with additional location in Vancouver, Canada and Oakland, California. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.